DSIP

DSIP – Delta Sleep-Inducing Peptide

Experimental Nonapeptide for Sleep Physiology, EEG Activity & Neuroendocrine Research

Delta Sleep-Inducing Peptide (DSIP) is a synthetic nonapeptide corresponding to a nine-amino-acid sequence originally described in research on sleep-associated biological factors.

DSIP was first characterized in 1977 following experiments involving cerebral venous blood collected from rabbits exposed to specific brain stimulation conditions.

Early investigations suggested that the peptide might influence slow-wave sleep, electroencephalographic (EEG) activity and sleep-related physiological responses.

These observations generated scientific interest in DSIP as a possible regulator of sleep-associated neural processes.

Subsequent investigations, however, produced inconsistent results.

Some experimental studies reported changes in sleep architecture, while others failed to reproduce significant sleep-promoting effects.

Furthermore, the endogenous biological origin, specific receptor and definitive mechanism of action of DSIP have not been conclusively established.

DSIP is therefore best understood as an experimental neuropeptide research compound rather than a clinically validated sleep-inducing agent.

Its scientific relevance extends to sleep physiology, peptide structure–activity relationships, neuroendocrine signaling and the investigation of sleep-associated biological mechanisms.

ICAME Pharmacy DSIP is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is DSIP?

DSIP stands for Delta Sleep-Inducing Peptide.

It is a nine-amino-acid peptide historically investigated for its possible effects on sleep-related brain activity.

The term delta refers to the low-frequency EEG activity commonly associated with deep non-rapid eye movement sleep.

DSIP became an important subject of experimental neuroscience research because early investigations suggested that a circulating peptide might influence sleep-associated electrical activity in the brain.

Researchers subsequently examined DSIP in relation to:

• Slow-wave sleep

• EEG delta activity

• Sleep architecture

• Sleep–wake regulation

• Neuroendocrine signaling

• Stress-associated physiological responses

• Hypothalamic biology

• Peptide metabolism

• Neuropeptide structure–activity relationships

Despite decades of investigation, the exact physiological role of DSIP remains unresolved.

DSIP Molecular Structure

DSIP is a nonapeptide consisting of nine amino acid residues.

Amino Acid Sequence

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

The sequence contains:

Trp – Tryptophan

Ala – Alanine

Gly – Glycine

Gly – Glycine

Asp – Aspartic Acid

Ala – Alanine

Ser – Serine

Gly – Glycine

Glu – Glutamic Acid

Molecular Characteristics

Compound Name: Delta Sleep-Inducing Peptide

Abbreviation: DSIP

Peptide Classification: Nonapeptide

Peptide Length: 9 Amino Acids

Molecular Formula: C₃₅H₄₈N₁₀O₁₅

Approximate Molecular Weight: 848.8 g/mol

CAS Number: 62568-57-4

Primary Research Field: Sleep and Neuroendocrine Physiology

These specifications describe the commonly referenced free-acid peptide sequence.

The exact identity, counterion and chemical form of the supplied research material should be confirmed through batch-specific analytical documentation.

Discovery and Scientific Background

DSIP was characterized in a landmark study published in Proceedings of the National Academy of Sciences in 1977.

Researchers investigated biological material obtained from rabbits subjected to experimental stimulation of specific thalamic regions.

They isolated and characterized a peptide associated with changes in EEG activity.

The identified sequence was:

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

The researchers subsequently synthesized the peptide and investigated its biological activity under experimental conditions.

These findings contributed to the development of the hypothesis that sleep regulation might involve circulating peptide signals.

However, later research raised questions about the identity of naturally occurring DSIP-like substances and whether the synthetic nonapeptide fully represents an endogenous mammalian sleep-regulating factor.

The discovery remains historically important, even though its original physiological interpretation has not been conclusively confirmed.

DSIP and Sleep Physiology

Sleep is a complex biological process regulated by interacting neural circuits, neurotransmitters, circadian signals and homeostatic mechanisms.

Two major sleep states are commonly recognized:

Non-Rapid Eye Movement (NREM) Sleep

Rapid Eye Movement (REM) Sleep

NREM sleep includes stages characterized by different patterns of brain activity.

The deepest NREM stage, commonly called N3 or slow-wave sleep, is associated with prominent low-frequency EEG oscillations.

DSIP was originally investigated because of reported effects on sleep-associated EEG patterns.

However, its influence on sleep architecture has not been consistently reproduced.

Accordingly, DSIP should not be described as a proven regulator of deep sleep.

DSIP and Delta-Wave Activity

Delta waves are low-frequency electrical oscillations recorded using electroencephalography.

They are particularly prominent during deep NREM sleep.

Delta activity is an important research marker for understanding sleep intensity and homeostatic sleep regulation.

Early DSIP experiments reported changes in slow-wave EEG activity.

Subsequent studies examined whether the peptide influenced:

Delta-wave activity

Slow-wave sleep duration

Sleep onset

Sleep continuity

Sleep architecture

Sleep-associated neural synchronization

However, experimental findings have been inconsistent.

Several studies failed to demonstrate reliable increases in slow-wave sleep or EEG delta power following DSIP administration.

Consequently, an increase in delta-wave activity should be treated as a historical experimental finding rather than an established effect of DSIP.

Proposed Mechanisms of DSIP

Unlike many well-characterized neuropeptides, DSIP does not have a conclusively established specific receptor.

Its endogenous precursor and associated gene have also remained uncertain.

This makes its pharmacology substantially less defined than that of peptides with identified receptor systems.

Historical Research Hypothesis

DSIP or DSIP-Like Peptide

↓

Possible Interactions with Neural or Endocrine Systems

↓

Hypothesized Modulation of Sleep-Related Signaling

↓

Experimental Changes in EEG or Neuroendocrine Responses

↓

Potential Sleep–Wake or Physiological Effects

This diagram represents an experimental hypothesis.

It does not describe a validated molecular pathway.

DSIP should not be presented as a confirmed agonist of a specific sleep receptor or as a proven activator of GABA, melatonin or other established sleep-regulating systems.

DSIP and Neuroendocrine Research

The neuroendocrine system connects neural activity with hormonal regulation.

The hypothalamus and pituitary gland play central roles in this communication.

Historical DSIP research has examined possible relationships with several hormonal pathways.

These include:

• Corticotropin-associated signaling

• Stress-related endocrine responses

• Growth hormone-associated physiology

• Hypothalamic regulation

• Pituitary signaling

• Neuroendocrine feedback

Some experimental studies reported changes in hormone-associated responses following exposure to DSIP.

However, the findings have not established a definitive endocrine mechanism or validated therapeutic application.

DSIP remains relevant to research examining how peptide-like biological signals may interact with neuroendocrine systems.

DSIP and Stress-Response Research

Physiological stress involves coordinated responses across the nervous, endocrine and immune systems.

The hypothalamic–pituitary–adrenal (HPA) axis is an important component of this response.

The HPA axis involves signaling between:

Hypothalamus

↓

Pituitary Gland

↓

Adrenal Glands

↓

Glucocorticoid-Associated Responses

Historical DSIP studies investigated possible interactions with stress-related hormonal activity.

Some experimental findings suggested that DSIP or DSIP-like substances might influence stress-associated physiological responses.

However, the evidence does not establish DSIP as an effective treatment for anxiety, stress disorders or abnormal cortisol regulation.

Its relevance remains experimental.

DSIP and Circadian Rhythm Research

Circadian rhythms are approximately 24-hour biological cycles that coordinate many physiological functions.

These include:

Sleep–wake timing

Hormonal secretion

Body temperature

Metabolic activity

Behavioral rhythms

The suprachiasmatic nucleus of the hypothalamus is a principal component of the mammalian circadian timing system.

DSIP has been discussed in research concerning sleep regulation and broader neuroendocrine rhythms.

However, there is insufficient evidence to conclude that DSIP directly resets the circadian clock or reliably corrects circadian rhythm disorders.

Circadian research should therefore be distinguished from DSIP's historical association with slow-wave sleep.

DSIP and Sleep Homeostasis

Sleep homeostasis refers to the regulation of sleep need as a function of prior wakefulness and sleep.

As wakefulness continues, homeostatic sleep pressure generally increases.

During sleep, this pressure gradually decreases.

Slow-wave EEG activity is often used as a physiological marker associated with homeostatic sleep regulation.

Because DSIP was historically linked to delta-wave activity, it became relevant to research examining possible biochemical mediators of sleep pressure.

However, the available evidence does not establish DSIP as an endogenous sleep-pressure signal.

Its relationship with sleep homeostasis remains uncertain.

DSIP and Human Sleep Research

DSIP has been evaluated in small human studies, including investigations involving people with chronic insomnia.

One double-blind study enrolled 16 patients with chronic insomnia.

Researchers examined objective and subjective sleep-related measures.

Some objective measures suggested modest improvements in sleep efficiency and sleep latency.

However, the investigators considered the statistically significant findings weak, and some differences could have resulted from changes in the placebo group.

Other sleep-related measures, including subjective sleep quality, did not demonstrate meaningful improvements.

The authors concluded that short-term DSIP treatment was unlikely to provide major therapeutic benefit for chronic insomnia.

These findings illustrate why early experimental observations should not be interpreted as proof of clinical efficacy.

DSIP and Polysomnography Research

Polysomnography is a method used to record physiological activity during sleep.

It may include:

EEG – Brain Electrical Activity

EOG – Eye Movements

EMG – Muscle Activity

Respiratory Measurements

Sleep Stage Classification

Historical DSIP studies used objective sleep measurements to examine possible changes in sleep architecture.

Relevant research endpoints included:

• Sleep latency

• Total sleep time

• Sleep efficiency

• NREM sleep

• REM sleep

• Slow-wave activity

• Sleep continuity

These measurements remain important in sleep research.

However, the use of polysomnography in a study does not establish that the investigated peptide produces clinically meaningful improvements.

DSIP and REM Sleep Research

Rapid Eye Movement (REM) sleep is a distinct physiological sleep state associated with characteristic EEG activity, eye movements and muscle atonia.

Early investigations of DSIP examined possible effects on both NREM and REM sleep.

Some animal studies reported species-dependent changes in sleep architecture.

Other studies failed to reproduce meaningful effects.

These inconsistent findings suggest that DSIP's relationship with REM sleep remains uncertain.

DSIP should not be described as a proven regulator of REM sleep or dreaming.

DSIP and Peptide Structure–Activity Relationships

Structure–activity relationship research examines how molecular structure influences biological activity.

DSIP is relevant to this field because researchers have investigated synthetic analogues containing modifications to its amino acid sequence.

Certain DSIP analogues demonstrated biological activity that differed from that of the original peptide in experimental models.

Some studies reported more pronounced slow-wave sleep-associated effects with specific modified analogues than with DSIP itself.

These observations suggest that peptide stereochemistry, structural modifications and enzymatic stability may influence experimental responses.

Importantly, findings involving DSIP analogues should not automatically be attributed to unmodified DSIP.

DSIP and Peptide Stability

Peptide stability is an important factor in experimental pharmacology.

Peptides may be susceptible to enzymatic degradation and other chemical changes.

The biological activity observed in an experimental system can depend on:

Molecular identity

Peptide integrity

Experimental conditions

Metabolic stability

Analytical purity

Assay methodology

Historical research into DSIP analogues has raised questions about whether peptide degradation influences observed biological effects.

However, the pharmacokinetic behavior of research-grade DSIP in humans has not been adequately established.

DSIP and Hypothalamic Biology

The hypothalamus participates in several essential physiological processes.

These include:

Sleep–wake regulation

Hormonal control

Temperature regulation

Energy balance

Stress responses

Circadian signaling

Historical immunochemical studies reported DSIP-like immunoreactivity in regions of the nervous system, including hypothalamic structures.

However, detecting DSIP-like immunoreactivity does not conclusively prove the presence of the exact synthetic DSIP sequence.

Cross-reactivity and the possible presence of structurally related molecules complicate interpretation.

The endogenous identity and physiological role of DSIP-like substances therefore remain important unresolved questions.

DSIP and the Search for Endogenous Sleep Factors

The idea that sleep might be regulated partly by circulating biochemical factors has a long history in neuroscience.

Researchers have investigated multiple candidate sleep-associated substances.

DSIP became a prominent historical example because of its early identification and proposed effects on EEG activity.

However, subsequent investigations revealed substantial challenges in establishing its endogenous biological role.

These challenges include:

• Uncertain endogenous molecular identity

• Lack of a confirmed specific receptor

• Lack of a definitively identified precursor gene

• Inconsistent experimental effects

• Limited clinical evidence

• Unresolved mechanisms

These limitations make DSIP scientifically interesting as an example of the challenges involved in identifying endogenous regulatory peptides.

DSIP and Other Sleep-Related Signaling Systems

Sleep physiology involves several well-characterized biological systems.

DSIP should not be described as equivalent to these established neurotransmitters or hormones.

Scientific Evidence and Research Limitations

DSIP has been investigated for several decades.

Its historical importance is well documented, but its biological role remains controversial.

Established Scientific Facts

• DSIP is a defined synthetic nonapeptide.

• Its commonly reported sequence contains nine amino acids.

• The peptide was characterized in early sleep-related experiments.

• DSIP and related analogues have been investigated in animal and human studies.

• Published results concerning sleep effects are inconsistent.

Important Uncertainties

• Whether the exact DSIP sequence functions as a major endogenous mammalian sleep factor

• Whether DSIP has a specific biological receptor

• Its definitive molecular mechanism

• Its reproducible effects on human sleep

• Its long-term human safety

• Its clinical effectiveness for insomnia

• Its relationship with stress-related disorders and circadian dysfunction

These uncertainties should be clearly communicated in scientific product descriptions.

Potential Research Applications

DSIP may be relevant to appropriately controlled scientific investigations involving:

• Sleep physiology

• Slow-wave sleep research

• EEG delta activity

• Sleep architecture

• Sleep–wake regulation

• Sleep homeostasis

• Neuropeptide pharmacology

• Neuroendocrine signaling

• Hypothalamic research

• Stress-associated hormonal pathways

• Circadian physiology

• Peptide structure–activity relationships

• Synthetic peptide analogues

• Peptide stability

• Comparative sleep research

• Experimental neuroscience

These are scientific research areas, not proven clinical applications.

DSIP Research Overview

Compound Name: Delta Sleep-Inducing Peptide

Abbreviation: DSIP

Classification: Synthetic Nonapeptide

Sequence: H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

Peptide Length: 9 Amino Acids

Molecular Formula: C₃₅H₄₈N₁₀O₁₅

Approximate Molecular Weight: 848.8 g/mol

CAS Number: 62568-57-4

Historical Research Area: Sleep-Associated EEG Activity

Additional Research Areas: Neuroendocrine Physiology / Peptide Pharmacology

Specific Receptor: Not conclusively identified

Clinical Efficacy for Insomnia: Not established

Product Information

Product Name: DSIP

Full Name: Delta Sleep-Inducing Peptide

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Experimental Neuropeptide

Research Areas: Sleep Physiology / EEG Research / Neuroendocrine Signaling

Intended Use: Laboratory Research & Development Only

The exact identity and specifications of the supplied material should be verified through manufacturer documentation.

Batch-specific information should include, where applicable:

• Verified amino acid sequence

• Molecular identity

• Chemical form and counterion

• Analytical purity

• Analytical methodology

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claims regarding pharmaceutical quality, sterility, clinical safety or therapeutic efficacy should be made without appropriate supporting documentation.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, sleep-treatment, sedative, anxiolytic or other clinical purposes. Not for direct administration to humans or animals.

DSIP is an experimental peptide with an incompletely characterized mechanism and insufficient clinical evidence supporting its use for insomnia or other sleep disorders.

The term sleep-inducing is part of the compound's historical name and should not be interpreted as a verified therapeutic claim.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, neuroscience, molecular biology, neuroendocrine signaling, experimental pharmacology and life sciences research.

Product information is presented with an emphasis on responsible research use, accurate product identification, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.